DUBLIN--(BUSINESS WIRE)--The "Prosthetic Heart Valve Market By Product: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The global prosthetic heart valves market was valued at $ 6,889.3 million in 2021 and is projected to reach $ 19,738.23 million by 2031, registering a CAGR of 11.1% from 2022 to 2031.
A prosthetic heart valve is a surgically implanted artificial device that replaces damaged heart valves caused by heart valve disorders. The flow of blood through the heart is controlled by heart valves. Inadequate blood flow is caused by a malfunctioning heart valve, which necessitates prosthetic heart valve surgery.
The use of prosthetic heart valves lowers the risk of death and morbidity associated with cardiac valve disease. Cardiac valve problems can be inherited or acquired, and the causes are occasionally unknown. Heart valve disease has no cure, although it can be prevented or delayed with the right medication and nutrition.
Transcatheter valve replacement is a recommended minimally invasive operation that includes implanting a replacement valve into an aortic valve location rather than removing the defective heart valve. Suture-less valves, anti-calcification technology, and polymer and carbon-based technologies are some of the alternative treatments for heart valve disease. Heart valve diseases such as valvular stenosis and valvular regurgitation can be treated with surgery. To prevent blood clots on a prosthetic heart valve, the patient is prescribed a blood thinning medicine for the rest of his or her life.
Increase in number of heart surgeries conducted, surge in aging population, and rise in patient base around the world act as the key driving forces of the global prosthetic heart valve market. Other factors that are boosting the global market include rise in healthcare expenditure and increase in awareness of effective diagnostic and treatment choices for heart valve problems.
Moreover, surge in demand for less invasive operations, technological advancements, and increase in prevalence of cardiac illnesses are likely to create profitable prospects for the global prosthetic heart valves market throughout the forecast period.
Furthermore, the global prosthetic heart valve market is benefiting from upsurge in disposable income in developed countries. However, reimbursement concerns, high development costs, and costly treatment, notably for the transcatheter aortic heart valve, are stifling the prosthetic heart valve market's global expansion. The global prosthetic heart valves market is further hampered by stringent government restrictions of social distancing and delayed manufacturing and dearth of experienced specialists.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the global prosthetic heart valve market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2021 to 2031 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of prosthetic heart valve used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key Market Segments
By Product
- Mechanical Heart Valve
- Tissue Heart Valve
- Stented Tissue Heart Valve
- Stentless Tissue Heart Valve
- Transcatheter Heart Valve
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbott
- Medtronic
- MERIL LIFESCIENCES
- Boston Scientific Corporation
- Micro Interventional Devices, Inc.
- Direct Flow medical, Inc.
- Edwards Lifesciences Corporation
- LivaNova PLC.
- JenaValve Technology, Inc.
- CryoLife, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/u1nd33
